YearPaper
2007 Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA. 2007, 104:13283–13288.
Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1940229/
2007 Kocher T, Superti-Furga G. Mass spectrometry-based functional proteomics: from molecular machines to protein networks. Nat Methods. 2007, 4(10):807–15.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/17901870
2007 Orchard S, Salwinski L, Kerrien S, Montecchi- Palazzi L, Oesterheld M, Stumpflen V, Ceol A, Chatr-aryamontri A, Armstrong J, Woollard P, Salama JJ, Moore S, Wojcik J, Bader GD, Vidal M, Cusick ME, Gerstein M, Gavin AC, Superti-Furga G, et al. The minimum information required for reporting a molecular interaction experiment (MIMIx). Nat Biotechnol. 2007, 25(8):894–8.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/17687370
2007 Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Köcher T, Superti-Furga G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets. Blood. 2007, 110:4055–4063.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/17720881
2007 Schuster C, Fernbach N, Rix U, Superti-Furga G, Holy M, Freissmuth M, Sitte HH, Sexl V. Selective serotonin reuptake inhibitors – A new modality for the treatment of lymphoma/leukaemia? Biochem Pharmacol. 2007, 74(9):1424–35.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/17709099
2008 Baumgartner C, Gleixner KV, Peter B, Ferenc V, Gruze A, Remsing Rix LL, Bennett KL, Samorapoompichit P, Lee FY, Pickl WF, Esterbauer H, Sillaber C, Superti-Furga G, Valent P. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1–PDGFRalpha. Exp Hematol, 2008 Oct;36(10):1244–53.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18619723
2008 Bürckstümmer T, Bennett KL. Analysis of cellular protein complexes by affinity purification and mass spectrometry. In Proteomics Methods Express 2008 (O’Connor CD and Hames BD, eds.), pp 119–134, Scion, Oxfordshire.
Abstract:
2008 De Keersmaecker K, Versele M, Cools J, Superti-Furga G, Hantschel O. Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCRABL1 fusion protein kinases. Leukemia. 2008, Dec;22(12):2208–16.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18784740
2008 Eggert US, Superti-Furga G. Drugs in Action. Nature Chem Biol, 2008 4(1):7–11.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18084271
2008 Filippakopoulos P, Kofler M, Hantschel O, Gish GD, Grebien F, Salah E, Neudecker P, Kay LE, Turk BE, Superti-Furga G, Pawson T, Knapp S. Structural coupling of Fes and Abl SH2-tyrosine kinase domains links substrate recognition and kinase activation. Cell. 2008 Sep 5;134(5): 793–803.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18775312
2008 Hantschel O, Gstoettenbauer A, Colinge J, Kaupe I, Bilban M, Burkard TR, Valent P, Superti-Furga G. The chemokine IL-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in CML. Molecular Oncology, Vol 2/Issue3/ October 2008, 272–281.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19383348
2008 Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma, 2008 Apr;49(4):615-9. Review.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18398720
2008 Henney A, Superti-Furga G. A network solution. Nature, 2008 Oct 9;455(7214):730–1.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18843342
2008 Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood, 2008 Jan 7; PMID: 18180381.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18180381
2008 Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, Press RD, Superti-Furga G, Druker BJ, Deininger MW. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia, 2008 Jun;22(6):1184–90.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18354488
2008 Soulat D, Bürckstümmer T, Westermayer S, Goncalves A, Bauch A, Stefanovic A, Hantschel O, Bennett KL, Decker T, Superti-Furga G. The DEAD-box helicase DDX3 is a TBK1 substrate required for IFN-beta production. EMBO J, 2008 Aug 6;27(15):2135–46.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18583960
2008 Superti-Furga G, Wieland F, Cesareni G. Finally: The digital, democratic age of scientific abstracts. FEBS Lett., 2008 Apr 9;582(8):1169.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18328821
2009 Aebersold R, Auffray C, ..., Superti-Furga G, et al. Report on EU-USA workshop: how systems biology can advance cancer research. Mol Oncol, 2009 Feb;3(1):9-17.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19383362
2009 Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M, Köcher T, Mechtler K, Bennett KL, Superti-Furga G. Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci USA, 2009 May 5;106(18): 7414-9. Epub 2009 Apr 20.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19380743
2009 Brehme M. Intercell – accelerating innovation. N Biotechnol, 2009 Apr;25(4):181-4. Epub 2009 Feb 21.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19429533
2009 Bürckstümmer T, Baumann C, Blüml S, Dixit E, Dürnberger G, Jahn H, Planyavsky M, Bilban M, Colinge J, Bennett KL, Superti-Furga G. An orthogonal proteomic-genomic screen identififies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol, 2009 Mar;10(3):266-72. Epub 2009 Jan 21.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19158679
2009 Fernbach NV, Planyavsky M, Müller A, Breitwieser FP, Colinge J, Rix U, Bennett KL. Acid elution and one-dimensional shotgun analysis on an orbitrap mass spectrometer – an application to drug affifinity chromatography. J 2009 Oct;8(10):4753-65.Proteome Res,.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19653696
2009 Habjan M, Pichlmair A, Elliott RM, Overby AK, Glatter T, Gstaiger M, Superti-Furga G, Unger H, Weber F. NSs protein of rift valley fever virus induces the specific degradation of the double stranded RNA-dependent protein kinase. J Virol, 2009 May;83(9):4365-75. Epub 2009 Feb 11.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19211744
2009 Karayel E, Bürckstümmer T, Weitzer S, Martinez J, Superti-Furga G. The TLR independent DNA recognition pathway in murine macrophages: Ligand features and molecular signature. Eur J Immunol, 2009 Jul;39(7):1929-36.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19551900
2009 Pichlmair A, Schulz O, Tan CP, Rehwinkel J, Kato H, Takeuchi O, Akira S, Way M, Schiavo G, Reis e Sousa C. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J Virol, 2009 Oct;83(20):10761-9. Epub 2009 Aug 5.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19656871
2009 Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia, 2009 Mar;23(3):477-85.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19039322
2009 Rix U, Remsing Rix LL, Terker AS, Fernbach NV, Hantschel O, Planyavsky M, Breitwieser FP, Herrmann H, Colinge J, Bennett KL, Augustin M, Till JH, Heinrich MC, Valent P, Superti-Furga G. A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profifiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia, Epub 2009 Nov 5.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19890374
2009 Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol, 2009 Sep;5(9):616-24.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19690537
2009 Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Böhm A, Herndlhofer S, Tschachler E, Superti-Furga G, Jäger U, Valent P. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest, 2009 Dec;39(12): 1098-109.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19744184
2009 Superti-Furga G. A biomedical adventurers’ guide to navigating between careers in academia and industry. Nat Rev Mol Cell Biol, 2009 Dec;10(12):884-7.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19859061
2009 Winger JA, Hantschel O, Superti-Furga G, Kuriyan J. The structure of the leukemia drug imatinib bound to human quinine reductase 2 (NQO2). BMC Struct Biol, 2009 Feb;9:7.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19236722
2010 Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Bluml S, Grebien F, Bruckner M, Pasierbek P, Aumayr K, Planyavsky M, Bennett KL, Colinge J, Knapp S, Superti-Furga G. CD14 is a co-receptor of Toll-like receptors 7 and 9. J Exp Med. 2010 Nov 22;207(12):2689-701. Epub 2010 Nov 15.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21078886
2010 Bluml S, Binder NB, Niederreiter B, Polzer K, Hayer S, Tauber S, Schett G, Scheinecker C, Kollias G, Selzer E, Bilban M, Smolen JS, Superti-Furga G, Redlich K. Anti-inflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum. 2010 Jun;62(6):1608-19.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20155834
2010 Colinge J, Rix U, Superti-Furga G. Novel global network scores to analyze kinase inhibitor profiles. 2010 Sep 9, ORSC & APORC, 305-313. Lecture Notes;
Abstract:
2010 Dixit E, Boulant S, Zhang Y, Lee AS, Odendall C, Shum B, Hacohen N, Chen ZJ, Whelan SP, Fransen M, Nibert ML, Superti-Furga G, Kagan JC. Peroxisomes are signaling platforms for antiviral innate immunity. Cell. 2010 May 14;141(4): 668-81. Epub 2010 May 6.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20451243
2010 Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, Haura EB. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol. 2010 Apr;6(4):291-9. Epub 2010 Feb 28.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20190765
2010 Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood. 2010 Oct 28;116(17):3278-85. Epub 2010 Jun 2.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20519627
2010 Wojcik J, Hantschel O, Grebien F, Kaupe I, Bennett KL, Barkinge J, Jones RB, Koide A, Superti-Furga G, Koide S. A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol. 2010 Apr;17(4):519-27. Epub 2010 Mar 28.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20357770
2011 Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hormann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood. 2011 Aug 18;118(7):1885-98.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21680801
2011 Goncalves A, Burckstummer T, Dixit E, Scheicher R, Gorna MW, Karayel E, Sugar C, Stukalov A, Berg T, Kralovics R, Planyavsky M, Bennett KL, Colinge J, Superti-Furga G. Functional dissection of the TBK1 molecular network. PLoS One. 2011;6(9):e23971.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21931631
2011 Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiterer S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G. Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell. 2011 Oct 14;147(2):306-19.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22000011
2011 Hantschel O, Grebien F, Superti-Furga G. Targeting allosteric regulatory modules in oncoproteins: “drugging the undruggable”. Oncotarget. 2011 Nov;2(11):828-9.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22084171
2011 Huber K, Superti-Furga G. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. Bioorg Med Chem. 2011 Jun 15;19(12):3616-24.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21306906
2011 Pichlmair A, Lassnig C, Eberle CA, Gorna MW, Baumann CL, Burkard TR, Burckstummer T, Stefanovic A, Krieger S, Bennett KL, Rulicke T, Weber F, Colinge J, Muller M, Superti-Furga G. IFIT1 is an antiviral protein that recognizes 5’-triphosphate RNA. Nat Immunol. 2011 Jul;12(7):624-30.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21642987
2011 Winter GE, Rix U, Lissat A, Stukalov A, Mullner MK, Bennett KL, Colinge J, Nijman SM, Kubicek S, Kovar H, Kontny U, Superti-Furga G. An integrated chemical biology approach identifies specific vulnerability of Ewing’s sarcoma to combined inhibition of Aurora kinases A and B. Mol Cancer Ther. 2011 Oct;10(10):1846-56.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21768330
2012 Goncalves A, Karayel E, Rice GI, Bennett KL, Crow YJ, Superti-Furga G, Bürckstümmer T. SAMHD1 is a nucleic acid-binding protein that is mislocalised due to Aicardi-Goutières syndrome-associated mutations. Human Mut. 2012 Jul;33(7):1116-22.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22461318
2012 Hantschel O, Grebien F, Superti-Furga G. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res. 2012 Oct 1;72(19):4890-5.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23002203
2012 Hantschel O, Superti-Furga G. Cell biology: a key driver of therapeutic innovation. J Cell Biol. 2012 Nov 12;199(4):571-5.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23148230
2012 Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU, Superti-Furga G, Sexl V. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol. 2012 Jan 29;8(3):285-93.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22286129
2012 Hopkins S, Linderoth E, Hantschel O, Suarez-Henriques P, Pilia G, Kendrick H, Smalley MJ, Superti-Furga G, Ferby I. Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis. Dev Cell. 2012 Sep 11;23(3):547-59.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22975324
2012 Kachaner D, Filipe J, Laplantine E, Bauch A, Bennett KL, Superti-Furga G, Israël A, Weil R. Plk1-dependent phosphorylation of optineurin provides a negative feedback mechanism for mitotic progression, Mol. Cell. 45, 553-66.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22365832
2012 Pichlmair A, Kandasamy K, Alvisi G, Mulhern O, Sacco R, Habjan M, Binder M, Stefanovic A, Eberle CA, Goncalves A, Bürckstümmer T, Müller AC, Fauster A, Holze C, Lindsten K, Goodbourn S, Kochs G, Weber F, Bartenschlager R, Bowie AG, Bennett KL, Colinge J, Superti-Furga G. Viral immune modulators perturb the human molecular network by common and unique strategies. Nature. 2012 Jul 26;487(7408):486-90.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22810585
2012 Sudol M, Cesareni G, Superti-Furga G, Just W. Special issue – modular protein domains. FEBS Lett. 2012 Aug 14;586(17):2571. Epub 2012 Jun 17.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22713655
2012 Winter GE, Rix U, Carlson SM, Gleixner KV, Grebien F, Gridling M, Müller AC, Breitwieser FP, Bilban M, Colinge J, Valent P, Bennett KL, White FM, Superti-Furga G. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem Biol. 2012 Nov;8(11):905-12.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23023260
2013 Abbas YM, Pichlmair A, Górna MW, Superti-Furga G, Nagar B. Structural basis for viral 5'-PPP-RNA recognition by human IFIT proteins. Nature. 2013 Feb 7;494(7435):60-4.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23334420
2013 Borgdorff V, Rix U, Winter GE, Gridling M, Müller AC, Breitwieser FP, Wagner C, Colinge J, Bennett KL, Superti-Furga G, Wagner SN. A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. Oncogene. 2013 Jun 3.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23728343
2013 Giambruno R, Grebien F, Stukalov A, Knoll C, Planyavsky M, Rudashevskaya EL, Colinge J, Superti-Furga G, Bennett KL. Affinity Purification Strategies for Proteomic Analysis of Transcription Factor Complexes. J Proteome Res. 2013 September 6; 12(9): 4018–4027.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23937658
2013 Mellacheruvu D, Wright Z, Couzens AL, Lambert J-P, St-Denis N, Li T, Mitev YV, Hauri S, Sardiu ME, Low TY, Halim VA, Bagshaw RD, Hubner NC, al-Hakim A, Bouchard A, Faubert D, Fermin D, Dunham WH, Goudreault M, Lin Z-Y, Gonzalez Badillo B, Pawson T, Durocher D, Coulombe B, Aebersold R, Superti-Furga S, Colinge J, Heck AJR, Choi H, Gstaiger M, Mohammed S, Cristea IM, Bennett KL, Washburn MP, Raught B, Ewing RM, Gingras A-C, Nesvizhskii A. The CRAPome: a Contaminant Repository for Affinity Purification Mass Spectrometry Data. Nature Methods May; 24(Suppl): S50–S51.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23921808
2013 Rebsamen M, Kandasamy RK, Superti-Furga G. Protein interaction networks in innate immunity. Trends Immunol. 2013 Jul 1. S1471-4906(13)00079-3;
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23827258
2013 Rix U, Colinge J, Blatt K, Gridling M, Remsing Rix LL, Parapatics K, Cerny-Reiterer S, Burkard TR, Jäger U, Melo J, Bennett KL, Valent P, Superti-Furga G. A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL. PLoS One. 2013; 8(10): e77155.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24130846
2013 Unger S, Górna MW, Le Béchec A, Do Vale-Pereira S, Bedeschi MF, Geiberger S, Grigelioniene G, Horemuzova E, Lalatta F, Lausch E, Magnani C, Nampoothiri S, Nishimura G, Petrella D, Rojas-Ringeling F, Utsunomiya A, Zabel B, Pradervand S, Harshman K, Campos-Xavier B, Bonafé L, Superti-Furga G, Stevenson B, Superti-Furga A. FAM111A Mutations Result in Hypoparathyroidism and Impaired Skeletal Development. Am J Hum Genet. 2013 May 14.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23684011
2013 Varjosalo M, Sacco R, Stukalov A, van Drogen A, Planyavsky M, Hauri S, Aebersold R, Bennett KL, Colinge J, Gstaiger M, Superti-Furga G. Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. Nat Methods. 2013 Apr;10(4):307-14.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23455922
2013 Liehl P, Zuzarte-Luís V, Chan J, Zillinger T, Baptista F, Carapau D, Konert M, Hanson KK, Carret C, Lassnig C, Müller M, Kalinke U, Saeed M, Chora AF, Golenbock DT, Strobl B, Prudêncio M, Coelho LP, Kappe SH, Superti-Furga G, Pichlmair A, Vigário AM, Rice CM, Fitzgerald KA, Barchet W, Mota MM. Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nat Med. 2013 Dec 22. doi: 10.1038/nm.3424. [Epub ahead of print]
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24362933
2013 Fritzsche R, Karra D, Bennett KL, Ang FY, Heraud-Farlow JE, Tolino M, Doyle M, Bauer KE, Thomas S, Planyavsky M, Arn E, Bakosova A, Jungwirth K, Hörmann A, Palfi Z, Sandholzer J, Schwarz M, Macchi P, Colinge J, Superti-Furga G, Kiebler MA. Interactome of two diverse RNA granules links mRNA localization to translational repression in neurons. Cell Rep. 2013 Dec 26;5(6):1749-62. doi: 10.1016/j.celrep.2013.11.023. Epub 2013 Dec 19.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24360960
2013 Upadhyay AS, Vonderstein K, Pichlmair A, Stehling O, Bennett KL, Dobler G, Guo JT, Superti-Furga G, Lill R, Overby AK, Weber F. Viperin is an iron-sulfur protein that inhibits genome synthesis of tick-borne encephalitis virus via radical SAM domain activity. Cell Microbiol. 2013 Nov 19. doi: 10.1111/cmi.12241. [Epub ahead of print]
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24245804
2013 Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol Syst Biol. 2013 Nov 5;9:705. doi: 10.1038/msb.2013.61.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24189400
2013 Bürckstümmer T, Banning C, Hainzl P, Schobesberger R, Kerzendorfer C, Pauler FM, Chen D, Them N, Schischlik F, Rebsamen M, Smida M, Fece de la Cruz F, Lapao A, Liszt M, Eizinger B, Guenzl PM, Blomen VA, Konopka T, Gapp B, Parapatics K, Maier B, Stöckl J, Fischl W, Salic S, Taba Casari MR, Knapp S, Bennett KL, Bock C, Colinge J, Kralovics R, Ammerer G, Casari G, Brummelkamp TR, Superti-Furga G, Nijman SM. A reversible gene trap collection empowers haploid genetics in human cells. Nat Methods. 2013 Oct;10(10):965-71.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24161985
2014 Karonitsch T, Dalwigk K, Holinka J, Niederreiter B, Steiner CW, Bilban M, Wanivenhaus A, Windhager R, Smolen JS, Kiener HP, Superti-Furga G.1. A dual role of MTOR in the rheumatoid mesenchymal tissue response to inflammation. Ann Rheum Dis. 2014 Mar 1;73 Suppl 1:A3-4. doi: 10.1136/annrheumdis-2013-205124.8.
Abstract: http://ard.bmj.com/content/73/Suppl_1/A3.3
2014 Liehl P, Zuzarte-Luís V, Chan J, Zillinger T, Baptista F, Carapau D, Konert M, Hanson KK, Carret C, Lassnig C, Müller M, Kalinke U, Saeed M, Chora AF, Golenbock DT, Strobl B, Prudêncio M, Coelho LP, Kappe SH, Superti-Furga G, Pichlmair A, Vigário AM, Rice CM, Fitzgerald KA, Barchet W, Mota MM. Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nat Med. 2014 Jan;20(1):47-53. doi: 10.1038/nm.3424. Epub 2013 Dec 22.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24362933
2014 Vladimer GI, Górna MW, Superti-Furga G. IFITs: Emerging Roles as Key Anti-Viral Proteins. Front Immunol. 2014 Mar 10;5:94. doi: 10.3389/fimmu.2014.00094. eCollection 2014.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24653722
2014 Bonafé L, Liang J, Gorna MW, Zhang Q, Ha-Vinh R, Campos-Xavier AB, Unger S, Beckmann JS, Le Béchec A, Stevenson B, Giedion A, Liu X, Superti-Furga G, Wang W, Spahr A, Superti-Furga A. MMP13 mutations are the cause of recessive metaphyseal dysplasia, Spahr type. Am J Med Genet A. 2014 May;164A(5):1175-9. doi: 10.1002/ajmg.a.36431. Epub 2014 Mar 19.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24648384
2014 Kainulainen M, Habjan M, Hubel P, Busch L, Lau S, Colinge J, Superti-Furga G, Pichlmair A, Weber F. Virulence Factor NSs of Rift Valley Fever Virus Recruits the F-Box Protein FBXO3 To Degrade Subunit p62 of General Transcription Factor TFIIH. J Virol. 2014 Mar;88(6):3464-73. doi: 10.1128/JVI.02914-13. Epub 2014 Jan 8.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24403578
2014 Colinge J, César-Razquin A, Huber K, Breitwieser FP, Májek P, Superti-Furga G. Building and exploring an integrated human kinase network: global organization and medical entry points. J Proteomics. 2014 Jul 31;107:113-27. doi: 10.1016/j.jprot.2014.03.028. Epub 2014 Apr 3.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24704859
2014 Eberle CA, Zayas M, Stukalov A, Pichlmair A, Alvisi G, Müller AC, Bennett KL, Bartenschlager R, Superti-Furga G. The lysine methyltransferase SMYD3 interacts with hepatitis C virus NS5A and is a negative regulator of viral particle production. Virology. 2014 Aug;462-463:34-41. doi: 10.1016/j.virol.2014.05.016. Epub 2014 Jun 14.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25092459
2014 Giansanti P, Preisinger C, Huber KV, Gridling M, Superti-Furga G, Bennett KL, Heck AJ. Evaluating the promiscuous nature of tyrosine kinase inhibitors assessed in A431 epidermoid carcinoma cells by both chemical- and phosphoproteomics. ACS Chem Biol. 2014 Jul 18;9(7):1490-8. doi: 10.1021/cb500116c. Epub 2014 May 14.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24804581
2014 Gridling M, Ficarro S, Breitwieser FP, Song L, Parapatics K, Colinge J, Haura EB, Marto J, Superti-Furga G, Bennett KL, Rix U. Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics. Mol Cancer Ther. 2014 Sep 4. pii: molcanther.0152.2014. [Epub ahead of print]
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25189542
2014 Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Göktürk C, Sanjiv K, Strömberg K, Pham T, Berglund UW, Colinge J, Bennett KL, Loizou JI, Helleday T, Knapp S, Superti-Furga G. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014 Apr 10;508(7495):222-7. doi: 10.1038/nature13194. Epub 2014 Apr 2.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24695225
2014 Snijder B, Kandasamy RK, Superti-Furga G. Toward effective sharing of high-dimensional immunology data. Nat Biotechnol. 2014 Aug;32(8):755-9. doi: 10.1038/nbt.2974.
Abstract: http://www.nature.com/nbt/journal/v32/n8/full/nbt.2974.html
2014 Winter GE, Radic B, Mayor-Ruiz C, Blomen VA, Trefzer C, Kandasamy RK, Huber KV, Gridling M, Chen D, Klampfl T, Kralovics R, Kubicek S, Fernandez-Capetillo O, Brummelkamp TR, Superti-Furga G. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nat Chem Biol. 2014 Sep;10(9):768-73. doi: 10.1038/nchembio.1590. Epub 2014 Jul 27.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25064833
2015 Dikoglu E, Alfaiz A, Gorna M, Bertola D, Chae JH, Cho TJ, Derbent M, Alanay Y, Guran T, Kim OH, Llerenar JC Jr, Yamamoto G, Superti-Furga G, Reymond A, Xenarios I, Stevenson B, Campos-Xavier B, Bonafé L, Superti-Furga A, Unger S. Mutations in LONP1, a mitochondrial matrix protease, cause CODAS syndrome. Am J Med Genet A. 2015 Mar 21. doi: 10.1002/ajmg.a.37029.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25808063
2015 Dixon SJ, Winter GE, Musavi LS, Lee ED, Snijder B, Rebsamen M, Superti-Furga G, Stockwell BR. Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. ACS Chem Biol. 2015 May 15.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25965523
2015 Fauster A, Rebsamen M, Huber KV, Bigenzahn JW, Stukalov A, Lardeau CH, Scorzoni S, Bruckner M, Gridling M, Parapatics K, Colinge J, Bennett KL, Kubicek S, Krautwald S, Linkermann A, Superti-Furga G. A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. Cell Death Dis. 2015 May 21;6:e1767. doi: 10.1038/cddis.2015.130.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25996294
2015 Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KV, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G. Pharmacological targeting of the Wdr5-MLL interaction in C/EBP_ N-terminal leukemia. Nat Chem Biol. 2015 Jul 13. doi: 10.1038/nchembio.1859.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26167872
2015 Heinz LX, Baumann CL, Köberlin MS, Snijder B, Gawish R, Shui G, Sharif O, Aspalter IM, Müller AC, Kandasamy RK, Breitwieser FP, Pichlmair A, Bruckner M, Rebsamen M, Blüml S, Karonitsch T, Fauster A, Colinge J, Bennett KL, Knapp S, Wenk MR, Superti-Furga G. The Lipid-Modifying Enzyme SMPDL3B Negatively Regulates Innate Immunity. Cell Rep. 2015 Jun 30;11(12):1919-28. doi: 10.1016/j.celrep.2015.05.006.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26095358
2015 Herdy B, Karonitsch T, Vladimer GI, Tan CS, Stukalov A, Trefzer C, Bigenzahn JW, Theil T, Holinka J, Kiener HP, Colinge J, Bennett KL, Superti-Furga G. The RNA-binding protein HuR/ELAVL1 regulates IFN-_ mRNA abundance and the type I IFN response. Eur J Immunol. 2015 May;45(5):1500-11. doi: 10.1002/eji.201444979. Epub 2015 Mar 12.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25678110
2015 Hofer A, Cremosnik GS, Müller AC, Giambruno R, Trefzer C, Superti-Furga G, Bennett KL, Jessen HJ. A Modular Synthesis of Modified Phosphoanhydrides. Chemistry. 2015 Jun 1. doi: 10.1002/chem.201500838.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26033174
2015 Köberlin MS, Snijder B, Heinz LX, Baumann CL, Fauster A, Vladimer GI, Gavin AC, Superti-Furga G. A Conserved Circular Network of Coregulated Lipids Modulates Innate Immune Responses. Cell. 2015 Jul 2;162(1):170-83. doi: 10.1016/j.cell.2015.05.051. Epub 2015 Jun 18.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26095250
2015 Kravtsova-Ivantsiv Y, Shomer I, Cohen-Kaplan V, Snijder B, Superti-Furga G, Gonen H, Sommer T, Ziv T, Admon A, Naroditsky I, Jbara M, Brik A, Pikarsky E, Kwon YT, Doweck I, Ciechanover A. KPC1-mediated ubiquitination and proteasomal processing of NF-_B1 p105 to p50 restricts tumor growth. Cell. 2015 Apr 9;161(2):333-47. doi: 10.1016/j.cell.2015.03.001.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25860612
2015 Krishnaswamy JK, Singh A, Gowthaman U, Wu R, Gorrepati P, Sales Nascimento M, Gallman A, Liu D, Rhebergen AM, Calabro S, Xu L, Ranney P, Srivastava A, Ranson M, Gorham JD, McCaw Z, Kleeberger SR, Heinz LX, Müller AC, Bennett KL, Superti-Furga G, Henao-Mejia J, Sutterwala FS, Williams A, Flavell RA, Eisenbarth SC. Coincidental loss of DOCK8 function in NLRP10-deficient and C3H/HeJ mice results in defective dendritic cell migration. Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):3056-61. doi: 10.1073/pnas.1501554112. Epub 2015 Feb 23.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25713392
2015 Lorenz S, Deng P, Hantschel O, Superti-Furga G, Kuriyan J. Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity. Biochem J. 2015 Jun 1;468(2):283-91. doi: 10.1042/BJ20141492.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/?term=lorenz+s+superti-furga
2015 Muellner MK, Mair B, Ibrahim Y, Kerzendorfer C, Lechtermann H, Trefzer C, Klepsch F, Müller AC, Leitner E, Macho-Maschler S, Superti-Furga G, Bennett KL, Baselga J, Rix U, Kubicek S, Colinge J, Serra V, Nijman SM. Targeting a cell state common to triple-negative breast cancers. Mol Syst Biol. 2015 Feb 19;11(1):789. doi: 10.15252/msb.20145664.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25699542
2015 Rebsamen M, Pochini L, Stasyk T, de Araújo ME, Galluccio M, Kandasamy RK, Snijder B, Fauster A, Rudashevskaya EL, Bruckner M, Scorzoni S, Filipek PA, Huber KV, Bigenzahn JW, Heinz LX, Kraft C, Bennett KL, Indiveri C, Huber LA, Superti-Furga G. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature. 2015 Jan 7. doi: 10.1038/nature14107.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25561175
2015 Sana TG, Baumann C, Merdes A, Soscia C, Rattei T, Hachani A, Jones C, Bennett KL, Filloux A, Superti-Furga G, Voulhoux R, Bleves S. Internalization of Pseudomonas aeruginosa Strain PAO1 into Epithelial Cells Is Promoted by Interaction of a T6SS Effector with the Microtubule Network. MBio. 2015 Jun 2;6(3). pii: e00712-15. doi: 10.1128/mBio.00712-15.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26037124
2015 Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, Cravatt B, Dahlin JL, Dhanak D, Edwards AM, Frederiksen M, Frye SV, Gray N, Grimshaw CE, Hepworth D, Howe T, Huber KV, Jin J, Knapp S, Kotz JD, Kruger RG, Lowe D, Mader MM, Marsden B, Mueller-Fahrnow A, Müller S, O'Hagan RC, Overington JP, Owen DR, Rosenberg SH, Roth B, Ross R, Schapira M, Schreiber SL, Shoichet B, Sundström M, Superti-Furga G, Taunton J, Toledo-Sherman L, Walpole C, Walters MA, Willson TM, Workman P, Young RN, Zuercher WJ. The promise and peril of chemical probes. Nat Chem Biol. 2015 Aug;11(8):536-41. doi: 10.1038/nchembio.1867. No abstract available. Erratum in: Nat Chem Biol. 2015 Aug;11(8):541. Roth, Brian [Corrected to Roth, Bryan] and Frederiksen, Mathias [Added].
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26248267
2015 Bigenzahn JW, Fauster A, Rebsamen M, Kandasamy RK, Scorzoni S, Vladimer GI, Mueller AC, Gstaiger M, Zuber J, Bennett KL, Superti-Furga G. An inducible retroviral expression system for tandem affinity purification mass-spectrometry-based proteomics identifies MLKL as an HSP90 client. Mol Cell Proteomics. 2015 Dec 29. pii: mcp.O115.055350.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26714523
2015 Blomen VA, Májek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, Staring J, Sacco R, van Diemen FR, Olk N, Stukalov A, Marceau C, Janssen H, Carette JE, Bennett KL, Colinge J, Superti-Furga G, Brummelkamp TR. Gene essentiality and synthetic lethality in haploid human cells. Science. 2015 Nov 27;350(6264):1092-6. doi: 10.1126/science.aac7557. Epub 2015 Oct 15.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26472760
2015 Blüml S, Sahin E, Saferding V, Goncalves-Alves E, Hainzl E, Niederreiter B, Hladik A, Lohmeyer T, Brunner JS, Bonelli M, Koenders MI, van den Berg WB, Superti-Furga G, Smolen JS, Schabbauer G, Redlich K. Phosphatase and tensin homolog (PTEN) in antigen-presenting cells controls Th17-mediated autoimmune arthritis. Arthritis Res Ther. 2015 Aug 26;17:230. doi: 10.1186/s13075-015-0742-y.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26307404
2015 César-Razquin A, Snijder B, Frappier-Brinton T, Isserlin R, Gyimesi G, Bai X, Reithmeier RA, Hepworth D, Hediger MA, Edwards AM, Superti-Furga G. A Call for Systematic Research on Solute Carriers. Cell. 2015 Jul 30;162(3):478-87. doi: 10.1016/j.cell.2015.07.022. Review.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26232220
2015 Harutyunyan AS, Giambruno R, Krendl C, Stukalov A, Klampfl T, Berg T, Chen D, Milosevic Feenstra JD, Jäger R, Gisslinger B, Gisslinger H, Rumi E, Passamonti F, Pietra D, Müller AC, Parapatics K, Breitwieser FP, Herrmann R, Colinge J, Bennett KL, Superti-Furga G, Cazzola M, Hammond E, Kralovics R. Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood. 2015 Nov 16. pii: blood-2015-09-668673.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26574608
2015 Hörmann K, Stukalov A, Müller AC, Heinz LX, Superti-Furga G, Colinge J, Bennett KL. A surface biotinylation strategy for reproducible plasma membrane protein purification and tracking of genetic and drug-induced alterations. J Proteome Res. 2015 Dec 24.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26699813
2015 Huber KV, Olek KM, Müller AC, Tan CS, Bennett KL, Colinge J, Superti-Furga G. Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling. Nat Methods. 2015 Nov;12(11):1055-7. doi: 10.1038/nmeth.3590. Epub 2015 Sep 21.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26389571
2015 Huber KV, Superti-Furga G. Profiling of Small Molecules by Chemical Proteomics. Methods Mol Biol. Dec 24, 2015;1394:211-8. doi: 10.1007/978-1-4939-3341-9_15.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26700051
2015 Licciardello MP, Müllner MK, Dürnberger G, Kerzendorfer C, Boidol B, Trefzer C, Sdelci S, Berg T, Penz T, Schuster M, Bock C, Kralovics R, Superti-Furga G, Colinge J, Nijman SM, Kubicek S. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation. Oncogene. 2015 Jul;34(29):3780-90. doi: 10.1038/onc.2014.319. Epub 2014 Sep 29.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25263445
2015 Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U, Eisenwort G, Hadzijusufovic E, Gridling M, Dutreix C, Hoermann G, Schwaab J, Radia D, Roesel J, Manley PW, Reiter A, Superti-Furga G, Valent P. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia. 2015 Sep 9. doi: 10.1038/leu.2015.242.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26349526
2015 Rebsamen M, Superti-Furga G. SLC38A9: a lysosomal amino acid transporter at the core of the amino acid-sensing machinery that controls MTORC1. Autophagy. 2015 Oct 2:0.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26431368
2015 Royer-Bertrand B, Castillo-Taucher S, Moreno-Salinas R, Cho TJ, Chae JH, Choi M, Kim OH, Dikoglu E, Campos-Xavier B, Girardi E, Superti-Furga G, Bonafé L, Rivolta C, Unger S, Superti-Furga A. Mutations in the heat-shock protein A9 (HSPA9) gene cause the EVEN-PLUS syndrome of congenital malformations and skeletal dysplasia. Sci Rep. 2015 Nov 24;5:17154. doi: 10.1038/srep17154.
Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657157/
2016 Gorelik A, Illes K, Heinz LX, Superti-Furga G, Nagar B. Crystal structure of mammalian acid sphingomyelinase. Nat Commun. 2016 Jul 20;7:12196. doi: 10.1038/ncomms12196.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27435900
2016 Gorelik A, Illes K, Superti-Furga G, Nagar B. Structural Basis for Nucleotide Hydrolysis by the Acid Sphingomyelinase-Like Phosphodiesterase SMPDL3A. J Biol Chem. 2016 Jan 20. pii: jbc.M115.711085.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26792860
2016 Köberlin MS, Heinz LX, Superti-Furga G. Functional crosstalk between membrane lipids and TLR biology. Curr Opin Cell Biol. 2016 Feb 16;39:28-36. doi: 10.1016/j.ceb.2016.01.010.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26895312
2016 Müller AC, Giambruno R, Weißer J, Májek P, Hofer A, Bigenzahn JW, Superti-Furga G, Jessen HJ, Bennett KL. Identifying Kinase Substrates via a Heavy ATP Kinase Assay and Quantitative Mass Spectrometry. Sci Rep. 2016 Jun 27;6:28107. doi: 10.1038/srep28107.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27346722
2016 Pathria G, Garg B, Borgdorff V, Garg K, Wagner C, Superti-Furga G, Wagner SN. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells. Cell Death Dis. 2016 Mar 10;7:e2135. doi: 10.1038/cddis.2015.369.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26962685
2016 Sdelci S, Lardeau CH, Tallant C, Klepsch F, Klaiber B, Bennett J, Rathert P, Schuster M, Penz T, Fedorov O, Superti-Furga G, Bock C, Zuber J, Huber KV, Knapp S, Müller S, Kubicek S. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. Nat Chem Biol. 2016 May 9. doi: 10.1038/nchembio.2080.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27159579
2016 Tortola L, Nitsch R, Bertrand MJ, Kogler M, Redouane Y, Kozieradzki I, Uribesalgo I, Fennell LM, Daugaard M, Klug H, Wirnsberger G, Wimmer R, Perlot T, Sarao R, Rao S, Hanada T, Takahashi N, Kernbauer E, Demiröz D, Superti-Furga G, Decker T, Pichler A, Ikeda F, Kroemer G, Vandenabeele P, Sorensen PH, Penninger JM. The Tumor Suppressor Hace1 Is a Critical Regulator of TNFR1-Mediated Cell Fate. Cell Rep. 2016 May 17;15(7):1481-92. doi: 10.1016/j.celrep.2016.04.032. Epub 2016 May 5.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27160902
2016 van Karnebeek CD, Bonafé L, Wen XY, Tarailo-Graovac M, Balzano S, Royer-Bertrand B, Ashikov A, Garavelli L, Mammi I, Turolla L, Breen C, Donnai D, Cormier V, Heron D, Nishimura G, Uchikawa S, Campos-Xavier B, Rossi A, Hennet T, Brand-Arzamendi K, Rozmus J, Harshman K, Stevenson BJ, Girardi E, Superti-Furga G, Dewan T, Collingridge A, Halparin J, Ross CJ, Van Allen MI, Rossi A, Engelke UF, Kluijtmans LA, van der Heeft E, Renkema H, de Brouwer A, Huijben K, Zijlstra F, Heisse T, Boltje T, Wasserman WW, Rivolta C, Unger S, Lefeber DJ, Wevers RA, Superti-Furga A. NANS-mediated synthesis of sialic acid is required for brain and skeletal development. Nat Genet. 2016 May 23. doi: 10.1038/ng.3578.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27213289
2016 Byrgazov K, Kastner R, Gorna M, Hoermann G, Koenig M, Lucini CB, Ulreich R, Benesch M, Strenger V, Lackner H, Schwinger W, Sovinz P, Haas OA, van den Heuvel-Eibrink M, Niemeyer CM, Hantschel O, Valent P, Superti-Furga G, Urban C, Dworzak MN, Lion T. NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors. Leukemia. 2016 Oct 7. doi: 10.1038/leu.2016.250.
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220134/
2016 Gorelik A, Heinz LX, Illes K, Superti-Furga G, Nagar B. Crystal Structure of the Acid Sphingomyelinase-Like Phosphodiesterase SMPDL3B Provides Insights into Determinants of Substrate Specificity. J Biol Chem. 2016 Sep 28. pii: jbc.M116.755801.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/27687724
2016 Martins R, Maier J, Gorki AD, Huber KV, Sharif O, Starkl P, Saluzzo S, Quattrone F, Gawish R, Lakovits K, Aichinger MC, Radic-Sarikas B, Lardeau CH, Hladik A, Korosec A, Brown M, Vaahtomeri K, Duggan M, Kerjaschki D, Esterbauer H, Colinge J, Eisenbarth SC, Decker T, Bennett KL, Kubicek S, Sixt M, Superti-Furga G, Knapp S. Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions. Nat Immunol. 2016 Oct 31. doi: 10.1038/ni.3590.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/27798618
2016 Matsumoto Y, La Rose J, Kent OA, Wagner MJ, Narimatsu M, Levy AD, Omar MH, Tong J, Krieger JR, Riggs E, Storozhuk Y, Pasquale J, Ventura M, Yeganeh B, Post M, Moran MF, Grynpas MD, Wrana JL, Superti-Furga G, Koleske AJ, Pendergast AM, Rottapel R. Reciprocal stabilization of ABL and TAZ regulates osteoblastogenesis through transcription factor RUNX2. J Clin Invest. 2016 Dec 1;126(12):4482-4496. doi: 10.1172/JCI87802.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/27797343
2016 Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U, Eisenwort G, Hadzijusufovic E, Gridling M, Dutreix C, Hoermann G, Schwaab J, Radia D, Roesel J, Manley PW, Reiter A, Superti-Furga G, Valent P. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia. 2016 Feb;30(2):464-72. doi: 10.1038/leu.2015.242.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/26349526
2016 Li J, Casteels T, Frogne T, Ingvorsen C, Honoré C, Courtney M, Huber KVM, Schmitner N, Kimmel RA, Romanov RA, Sturtzel C, Lardeau CH, Klughammer J, Farlik M, Sdelci S, Vieira A, Avolio F, Briand F, Baburin I, Májek P, Pauler FM, Penz T, Stukalov A, Gridling M, Parapatics K, Barbieux C, Berishvili E, Spittler A, Colinge J, Bennett KL, Hering S, Sulpice T, Bock C, Distel M, Harkany T, Meyer D, Superti-Furga G, Collombat P, Hecksher-Sørensen J, and Kubicek S. Artemisinins Target GABAA Receptor Signaling and Impair α Cell Identity, Cell 2017 Jan 12 (epub ahead of print 2016 Dec 1);168(1), 86-100. doi:10.1016/j.cell.2016.11.010.
Abstract: http://www.cell.com/cell/abstract/S0092-8674(16)31531-8
Abstract:
2017 Filipek PA, de Araujo MEG, Vogel GF, De Smet CH, Eberharter D, Rebsamen M, Rudashevskaya EL, Kremser L, Yordanov T, Tschaikner P, Fürnrohr BG, Lechner S, Dunzendorfer-Matt T, Scheffzek K, Bennett KL, Superti-Furga G, Lindner HH, Stasyk T, Huber LA. LAMTOR/Ragulator is a negative regulator of Arl8b- and BORC-dependent late endosomal positioning. J Cell Biol. 2017 Oct 9. pii: jcb.201703061. doi: 10.1083/jcb.201703061. [Epub ahead of print]
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28993467
2017 Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 2017 Nov;31(11):2388-2397. doi: 10.1038/leu.2017.245. Epub 2017 Jul 31.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28757617
2017 Sedlyarova N, Rescheneder P, Magán A, Popitsch N, Rziha N, Bilusic I, Epshtein V, Zimmermann B, Lybecker M, Sedlyarov V, Schroeder R, Nudler E. Natural RNA Polymerase Aptamers Regulate Transcription in E. coli. Mol Cell. 2017 Jul 6;67(1):30-43.e6. doi: 10.1016/j.molcel.2017.05.025. Epub 2017 Jun 22.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28648779
2017 Radic-Sarikas B, Halasz M, Huber KVM, Winter GE, Tsafou KP, Papamarkou T, Brunak S, Kolch W, Superti-Furga G. Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter. Sci Rep. 2017 Jun 8;7(1):3091. doi: 10.1038/s41598-017-03129-6.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28596528
2017 Vladimer GI, Snijder B, Krall N, Bigenzahn JW, Huber KVM, Lardeau CH, Sanjiv K, Ringler A, Berglund UW, Sabler M, de la Fuente OL, Knöbl P, Kubicek S, Helleday T, Jäger U, Superti-Furga G. Global survey of the immunomodulatory potential of common drugs. Nat Chem Biol. 2017 Jun;13(6):681-690. doi: 10.1038/nchembio.2360. Epub 2017 Apr 24.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28437395
2017 Valent P, Herndlhofer S, Schneeweiß M, Boidol B, Ringler A, Kubicek S, Gleixner KV, Hoermann G, Hadzijusufovic E, Müllauer L, Sperr WR, Superti-Furga G, Mannhalter C. TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. Oncotarget. 2017 Apr 4;8(14):23061-23072. doi: 10.18632/oncotarget.15481.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28416739
2017 Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget. 2017 Apr 4;8(14):22606-22615. doi: 10.18632/oncotarget.15146.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28186983
2017 Conte C, Roscini L, Sardella R, Mariucci G, Scorzoni S, Beccari T, Corte L. Toll Like Receptor 4 Affects the Cerebral Biochemical Changes Induced by MPTP Treatment. Neurochem Res. 2017 Feb;42(2):493-500. doi: 10.1007/s11064-016-2095-6. Epub 2017 Jan 21.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28108849
2017 Korcsmaros T, Schneider MV, Superti-Furga G. Next generation of network medicine: interdisciplinary signaling approaches. Integr Biol (Camb). 2017 Feb 20;9(2):97-108. doi: 10.1039/c6ib00215c. Review.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28106223
2017 Radic-Sarikas B, Tsafou KP, Emdal KB, Papamarkou T, Huber KV, Mutz C, Toretsky JA, Bennett KL, Olsen JV, Brunak S, Kovar H, Superti-Furga G. Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities. Mol Cancer Ther. 2017 Jan;16(1):88-101. doi: 10.1158/1535-7163.MCT-16-0235. Epub 2016 Nov 15.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28062706